Recent advances in understanding and managing T-cell lymphoma

Yi, Jun; Kim, Seok Jin; Kim, Won Seog

doi:10.12688/f1000research.12573.1

Cited by 4 publications

(1 citation statement)

References 131 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brentuximab vedotin was also recently approved with chemotherapy for first-line CD30 + PTCL following data from the ECHELON-2 Phase III trial [ 11 ]. However, most patients are either refractory to initial therapy or relapse despite consolidative autologous stem cell transplantation [ 12 , 13 ]. At present, treatment options are limited for many patients with relapsed/refractory PTCL, and a median OS of just 6 months is reported following relapse or progression in patients treated with chemotherapy [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study

et al. 2019

View full text Add to dashboard Cite

Background Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL. Objective As the distribution of PTCL subtypes differs between populations and few patients in the pivotal trial of pralatrexate were Asian, this study investigated the safety and efficacy of pralatrexate as monotherapy in Chinese patients with R/R PTCL. Patients and Methods In this single-arm, open-label, multicenter study, 71 patients with R/R PTCL (median [range] 2 [1–14] prior systemic treatments) were recruited from 15 centers in China and received pralatrexate IV 30 mg/m 2 /week for 6 weeks in 7-week cycles (with vitamin B 12 /folate). The primary endpoint was objective response rate (ORR) per central review (null hypothesis: ORR < 15%). Results The study’s primary objective was met: ORR (95% CI) was 52% (40–64%) ( p < 0.001) and responses were observed across pre-specified patient subgroups. Median (95% CI) duration of response was 8.7 (3.3–14.1) months and first response was observed in Cycle 1 for most (84%) patients. Median (95% CI) progression-free survival and overall survival was 4.8 (3.1–8.1) months and 18.0 (10.4–NA) months, respectively. The most common treatment-emergent adverse events were stomatitis (68% [Grade 3/4: 20%]), anemia (49% [Grade 3/4: 24%]) and alanine aminotransferase increase (41% [Grade 3/4: 4%]). Conclusions These results demonstrate that pralatrexate may represent a promising treatment option for Chinese patients with R/R PTCL. The ORR of 52% compared favorably with prior studies of pralatrexate in other populations and there were no unanticipated side effects. Trial Registration ClinicalTrials.gov identifier: NCT03349333.

show abstract

Section: Introductionmentioning

confidence: 99%

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study

et al. 2019

View full text Add to dashboard Cite

show abstract

The role of allogeneic hematopoietic stem cell transplantation in adults with mature T-cell lymphomas

Stocker

Thielecke

Schmitz

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis

Hong

Yoon

et al. 2019

Sci Rep

Self Cite

View full text Add to dashboard Cite

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin’s lymphomas with poor clinical outcomes. Pralatrexate showed efficacy and safety in recurrent or refractory PTCLs. The purpose or this study was to investigate the efficacy and safety of pralatrexate in relapsed or refractory PTCLs in real-world practice. This was an observational, multicenter, retrospective analysis. Between December 2012 and December 2016, a total of 38 patients with relapsed or refractory PTCLs were treated with pralatrexate at 10 tertiary hospitals in Korea. Patients received an intravenous infusion of pralatrexate at a dose of 30 mg/m2/week for 6 weeks on a 7-week schedule. Modified dosing and/or scheduling was allowed according to institutional protocols. Median patient age was 58 years (range, 29–80 years) and the most common subtype was peripheral T-cell lymphoma, not otherwise specified (n = 23, 60.5%). The median dosage of pralatrexate per administration was 25.6 mg/m2/wk (range, 15.0–33.0 mg/m2/wk). In intention-to-treat analysis, 3 patients (7.9%) showed a complete response and 5 patients (13.2%) showed a partial response, resulting in an overall response rate (ORR) of 21.1%. The median duration of response was 7.6 months (range, 1.6–24.3 months). The median progression-free survival (PFS) was 1.8 months (95% confidence interval [CI], 1.7–1.8 months) and the median overall survival was 7.7 months (95% CI, 4.4–9.0 months). The most common grade 3/4 adverse events were thrombocytopenia (n = 13, 34.2%), neutropenia (n = 7, 23.7%), and anemia (n = 7, 18.4%). Our study showed relatively lower ORR and shorter PFS in patients with recurrent or refractory PTCLs treated with pralatrexate in real-world practice. The toxicity profile was acceptable and manageable. We also observed significantly lower dose intensity of pralatrexate in real-world practice.

show abstract

Recent advances in understanding and managing T-cell lymphoma

Cited by 4 publications

References 131 publications

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study

The role of allogeneic hematopoietic stem cell transplantation in adults with mature T-cell lymphomas

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis

Contact Info

Product

Resources

About